In:
Journal of Translational Medicine, Springer Science and Business Media LLC, Vol. 11, No. 1 ( 2013-12)
Abstract:
This study was designed to determine whether advanced non-small-cell lung cancer (NSCLC) patients with high copy number of epidermal growth factor receptor (EGFR) can benefit from treatment with EGFR-tyrosine kinase inhibitors (TKIs). Methods EGFR gene copy number was assessed by fluorescence in situ hybridization (FISH) and EGFR mutations was tested using Luminex xTAG technology in 502 TKI-treated NSCLC patients. The association between both biomarkers and clinical benefit from EGFR-TKI were analyzed. Results EGFR FISH + and EGFR mutations were significantly associated with higher response rates (37.2% and 43.7%, respectively), superior progression-free survival (PFS) (FISH+, 11.2 months; hazard ratio [HR], 0.51; 95% CI, 0.42 to 0.62; p 〈 0.001; mutation+, 11.7 months; HR, 0.37; 95% CI, 0.31 to 0.45; p 〈 0.001) and overall survival (OS) (FISH+, 30.2 months; HR, 0.51; 95% CI, 0.40 to 0.65; p 〈 0.001; mutation+, 30.2 months; HR, 0.45; 95% CI, 0.36 to 0.58; p 〈 0.001). In patients with wild-type EGFR, EGFR FISH + correlated with longer PFS than EGFR FISH- status (4.4 months vs . 2.0 months; HR, 0.56; 95% CI, 0.41 to 0.75; p 〈 0.001), so did amplification (5.0 months vs . 2.0 months; HR, 0.43; 95% CI, 0.24 to 0.76; p = 0.003). However, FISH + had no association with improved PFS in EGFR-mutated patients (HR, 0.77; 95% CI, 0.57 to 1.03; p = 0.076). Conclusions A combined analysis of EGFR FISH and mutation is an effective predictor of EGFR-TKI therapy. Specifically, a high EGFR copy number may predict benefit from TKIs treatment for NSCLC patients with wild-type EGFR.
Type of Medium:
Online Resource
ISSN:
1479-5876
DOI:
10.1186/1479-5876-11-90
Language:
English
Publisher:
Springer Science and Business Media LLC
Publication Date:
2013
detail.hit.zdb_id:
2118570-0
Permalink